H Tindall

COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS

Robert Altman, L Carreras, Rubén Sierra Díaz et al. · Oxford University Research Archive (ORA) (University of Oxford) · 1994 · 3.3K citations

Thrombosis, Ischemic Stroke, Cardiovascular Disease +9

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Hiddo J.L. Heerspink, Hans‐Henrik Parving, Dennis L. Andress et al. · The Lancet · 2019 · 589 citations · Full text

Urology, Renal Disease, Renal Events +7

Independent and Additive Impact of Blood Pressure Control and Angiotensin II Receptor Blockade on Renal Outcomes in the Irbesartan Diabetic Nephropathy Trial

Marc A. Pohl, Samuel S. Blumenthal, D Cordonnier et al. · Journal of the American Society of Nephrology · 2005 · 373 citations

Time to stop counting the tablets?

T Pullar, S Kumar, H Tindall et al. · Clinical Pharmacology & Therapeutics · 1989 · 233 citations

Drug Safety, Non-pharmacological Intervention, Preventive Medicine +13

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

PK Judge, Natalie Staplin, KJ Mayne et al. · The Lancet Diabetes & Endocrinology · 2023 · 88 citations · Full text